Tuesday, July 1, 2025 7/1/2025

Therapeutic targeting of Wnt signaling in cancer

Award Number: R01CA269377
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 12/01/2022
PERIOD OF PERFORMANCE END DATE: 11/30/2027

Group Awards By:

View Award Description

Therapeutic targeting of Wnt signaling in cancer - Project Summary/Abstract The overarching goal of our research program is to develop small-molecule anticancer drugs. We focus herein on a new chemical method to control aberrant Wnt/β-catenin signaling that drives tumorigenesis and metastasis of many cancers, in particular, colorectal cancer (CRC). CRC affects about 4% of the population and caused ~60,000 deaths in 2021. Despite decades of effort, drugging this oncogenic pathway has not been successful. In 2009, we reported for the first time that Wnt/β-catenin signaling can be intercepted by small molecules. Catalytic inhibition of tankyrases prevents the turnover of the Axin, which leads to a rapid accumulation of Axin. The accumulated Axin then stabilizes the β-catenin destruction complex (DC) to facilitate the degradation of β-catenin. However, using this strategy to treat cancer has not been successful. Recent studies suggest that tankyrases can, paradoxically, support Wnt/β-catenin signaling through molecular scaffolding. The unexpected dichotomous mode of action potentially explains the unsatisfactory outcomes of various preclinical studies of tankyrase inhibitors. Although the mechanism by which tankyrases sustain Wnt/β- catenin signaling is not clear, mounting evidence suggests that the tankyrase aggregation is responsible for it. In this study, we will develop a chemical strategy to control the catalysis-independent function of tankyrases. We will then use this new tool to study how tankyrases affect the dynamic assembly of DC. We will further use a proteomic approach to delineate the catalytic and scaffolding functions of tankyrases with detailed characterization of their mode of action. This work will help us understand how tankyrases control multiple signaling pathways important to cancer. Additionally, we will compare the responsiveness of a large panel of immortalized human colonic epithelial cell lines and CRC cell lines toward tankyrase inhibition and depletion. We will then corroborate the results with in vivo studies. Correlating the cellular sensitivity with their genetic background will provide potential biomarkers and inform therapeutic strategies for cancers. Overall, this project will address the unsolved issue in drugging the Wnt/β-catenin pathway and improve our understanding of how tankyrases control Wnt/β-catenin signaling.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $648,718 )
2025	2025	THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER	5323 HARRY HINES BLVD	DALLAS	TX	75390	DALLAS	USA	Cancer Treatment Research	000	3	11/6/2024	NON-COMPETING CONTINUATION	$583,848
2025	2025	THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER	5323 HARRY HINES BLVD	DALLAS	TX	75390	DALLAS	USA	Cancer Treatment Research	001	3	6/4/2025	NON-COMPETING CONTINUATION	$64,870
														Subtotal = $648,718

Issue Date FY: 2024 ( Subtotal = $616,283 )
2024	2024	THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER	5323 HARRY HINES BLVD	DALLAS	TX	75390	DALLAS	USA	Cancer Treatment Research	001	2	4/17/2024	NON-COMPETING CONTINUATION	$32,435
2024	2024	UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER, THE	5323 HARRY HINES BLVD	DALLAS	TX	75390	DALLAS	USA	Cancer Treatment Research	000	2	11/3/2023	NON-COMPETING CONTINUATION	$583,848
														Subtotal = $616,283

Issue Date FY: 2023 ( Subtotal = $648,718 )
2023	2023	UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER, THE	5323 HARRY HINES BLVD	DALLAS	TX	75390	DALLAS	USA	Cancer Treatment Research	000	1	11/23/2022	NEW	$648,718
														Subtotal = $648,718

Grand Total All Awards = $1,913,719

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Therapeutic targeting of Wnt signaling in cancer

Award Number: R01CA269377

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 12/01/2022

PERIOD OF PERFORMANCE END DATE: 11/30/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer